

Meeting the Editorial Advisory Board

Editorial advisors representing diverse areas in the pharmaceutical sciences from North America, Europe, and Asia are appointed for a three-year term. In addition to his/her customary advisory function to the editorial team, each member has the additional responsibility of reviewing 12 manuscripts within two weeks of receipt for the journal. Those members

with expertise in computational chemistry and biology, molecular biology and pharmacology, clinical pharmacology, pharmacoconomics, pharmacoepidemiology, or disease state management are appointed to help grow these currently underrepresented areas in the journal. Future board members will be recruited from the reviewer pool.



Jessie L.-S. Au received her Pharm.D. in 1972 and Ph.D. in Pharmaceutics in 1980 from the University of California at San Francisco. After a one year post-doc in Biochemical Pharmacology at Roswell Park Memorial Institute and an additional three years as a cancer research scientist, she joined the faculty of The Ohio State University, where she rose through the ranks to Professor in 1992. Dr. Au received several major awards from the NIH, including the prestigious MERIT Award in 1992. In the same year, she received a Distinguished Scholar Award from The Ohio State University and was named to the Dorothy M. Davis Chair of Cancer Research. In addition to being a Professor of Pharmaceutics, Dr. Au is Deputy Director of the OSU Comprehensive Cancer Center. Her research is on pharmacokinetics and pharmacodynamics of anti-cancer and anti-AIDS agents.



Ronald T. Borchardt is the Solon E. Summerfield Distinguished Professor and Chairman of the Department of Pharmaceutical Chemistry at The University of Kansas,

Lawrence, KS. He received his undergraduate education (B.S. in Pharmacy, 1967) from the University of Wisconsin-Madison and his graduate education (Ph.D. in Medicinal Chemistry, 1970) from The University of Kansas-Lawrence. After serving as a Postdoctoral Fellow at the National Institutes of Health, he returned to The University of Kansas as a Professor. His research interests include the application of cell culture systems to study drug transport, the development of strategies to improve the membrane permeabilities of peptides and the development of strategies for stabilizing proteins to chemical degradation.



Professor S. S. (Bob) Davis obtained his Bachelors degree in Pharmacy from the School of Pharmacy at the University of London in 1964 and a PhD in colloid science at the same university in 1967. He was awarded his Doctor of Science degree (higher doctorate) in 1982. In 1968 he was awarded a one year Fulbright Scholarship to undertake postdoctoral studies with Professor Takeru Higuchi at the University of Kansas in the field of solution thermodynamics. Professor Davis took up his present position of Lord Trent Professor at Nottingham in 1975. Topics of research include drug targeting (with particular emphasis on colloidal carriers), transmucosal delivery, oral and parenteral systems for controlled release.



Kathleen M. Giacomini received her Ph.D. in Pharmaceutics from the State University of New York at Buffalo in 1979 and carried out post-doctoral studies at Stanford University in Clinical Pharmacology. She is currently Professor of Pharmacy, Pharmaceutical Chemistry and Pharmacology at the University of California San Francisco. Dr. Giacomini's research focuses on the targeting and disposition of drugs. She is particularly interested in the transport of organic cations and nucleosides and nucleoside analogs across renal and choroid plexus epithelia.




Jonathan Hadgraft is Professor and Chairman of Pharmaceutical Chemistry at the Welsh School of Pharmacy in the United Kingdom. He was educated at the University of Oxford with M.A. and D. Phil in Chemistry. In 1991 he was awarded D.Sc. by the Faculty of Clinical Medicine (University of Oxford). He has held teaching positions at the University of London, Strathclyde, and Nottingham. A fellow of the Royal Society of Chemistry and the American Association of Pharmaceutical Scientists, his research interests are the application of physical chemistry to controlled drug delivery with particular emphasis on the mechanisms of percutaneous absorption and transdermal delivery.



Abraham (Bram) G. Hartzema, Pharm.D., M.S.P.H., Ph.D. is Professor of Pharmacy Administration in the School of

Pharmacy and Clinical Professor of Health Policy and Administration in the School of Public Health at the University of North Carolina at Chapel Hill. He is also Research Associate of the Cecil G. Sheps Center for Health Services Research and Director of the UNC Center of Pharmaceutical Outcomes Research. His major research interests are pharmacoepidemiology, pharmaceutical outcomes research, program evaluation and health services research.




Mitsuru Hashida is a Professor of Pharmaceutics and Drug Delivery Research on the Faculty of Pharmaceutical Sciences at Kyoto University, Japan. He received his Ph.D. degree from Kyoto University in 1979 and became a faculty member in 1980 following postdoctoral studies at the University of Kansas. His research interests are in drug targeting systems with macromolecular and particulate carriers as well as transdermal delivery. Dr. Hashida is an associate editor of the *Journal of Drug Targeting* and is serving on the Executive Council of the Japan Society of Drug Delivery System and on the Board of Governors of the Controlled Release Society.




Brian B. Hoffman received a medical degree from McGill University where he completed clinical training in internal medicine and clinical pharmacology. After a research fellowship at Duke University, Dr. Hoffman joined the faculty at the Stanford University School of Medicine in California, where he is currently Professor of Medicine and Molecular Pharmacology. His laboratory is based in the Geriatrics Research Education and Clinical Center at the Veterans Affairs Palo Alto Health Care System. Dr. Hoffman's research interests relate primarily to adrenergic pharmacology.



Michael J. Pikal, Ph.D., is a Senior Research Scientist with the Lilly Research Laboratories and an Adjunct Professor of Pharmaceutics at the University of Michigan and at the University of Minnesota. He received his Ph.D. in physical chemistry (1966) from Iowa State University and was a Post-doctoral Research Fellow with the Lawrence Livermore Laboratory (1966-1967). His research activities include solid state chemistry of pharmaceuticals and the science and technology of freeze drying.



Wei-Chiang Shen, Ph.D. (Chemistry, Boston University, Boston, 1972), is a Professor of Pharmaceutical Sciences at the University of Southern California School of Pharmacy, and is a Fellow of the American Association of Pharmaceutical Scientists. His research interests have been focused on cellular uptake of macromolecular conjugates and its applications in drug delivery and targeting. His current research topics include transferrin receptor-mediated transcytosis in epithelial cells and lipid-conjugation in peptide drug delivery systems.



Keiji Yamamoto is Professor of Pharmaceutical Technology at the Faculty of Pharmaceutical Science, Chiba University, Japan. He graduated in 1971 from Chiba University with the degree of Bachelor of Pharmacy and in 1973 with the degree of Master of Pharmacy. In 1976, he obtained his Ph.D. degree from Hokkaido University. In 1983, he spent a year as Research Fellow at the College of Pharmacy, University of Utah, under the supervision of Prof. W.I. Higuchi. His research interests are focused on the mechanochemistry of


crystalline medicinals and the interaction between medicinal and pharmaceutical additives.



Tetsuya Kamataki is a Professor in the Division of Drug Metabolism, Faculty of Pharmaceutical Sciences, Hokkaido University, Japan. He received his B.S. and M.S. degrees from the University of Chiba and his Ph.D. degree from the University of Tokyo. An editorial board member of numerous international journals, he is presently an Associate Editor of *Biochemical Pharmacology*. His research interest is in drug metabolism as relates to molecular toxicology.



Harold G. Boxenbaum is Director of Pharmacokinetics at Otsuka America Pharmaceuticals, Inc. in Rockville, Maryland. His researchs interest include clinical pharmacology in drug development, interspecies pharmacokinetic scaling and longevity hormesis (paradoxical life prolongation by low doses of toxic agents).



Robert Gurny is Professor and Head of the Department of Biopharmaceutics and Physical Pharmacy at the University of Geneva, Switzerland where he earned both his BS in pharmacy and his Ph.D. in physical pharmacy. He later earned a degree in statistics and computer science. Dr. Gurny's major research interests include pharmaceutical processing and the use of polymers in the design of new controlled-drug-release systems.